Who are AG-348's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pyrukynd, Placebo Matching Mitapivat.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ag-348.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AG-348 — Competitive Intelligence Brief

AG-348 (AG-348) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyruvate kinase activator. Area: Hematology.

phase 3 Pyruvate kinase activator Pyruvate kinase R (PKR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

AG-348 (AG-348) — Agios Pharmaceuticals, Inc.. AG-348 activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and reduce hemolysis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AG-348 TARGET	AG-348	Agios Pharmaceuticals, Inc.	phase 3	Pyruvate kinase activator	Pyruvate kinase R (PKR)
Pyrukynd	MITAPIVAT	Agios Pharms Inc	marketed	Pyruvate Kinase Activator [EPC]	Pyruvate kinase PKLR	2022-01-01
Placebo Matching Mitapivat	Placebo Matching Mitapivat	Agios Pharmaceuticals, Inc.	phase 3	Pyruvate kinase activator	Pyruvate kinase R (PKR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyruvate kinase activator class)

Agios Pharmaceuticals, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AG-348 — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-348. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab